What the Neuroplasticity Literature Says About Semax, Selank and DSIP

The short version

Clarity Peptide Labs is a reference desk for three peptides studied for effects on the brain: semax, selank, and DSIP (delta sleep-inducing peptide). A peptide is a short chain of amino acids that can take part in biological signaling.

The idea connecting these compounds is neuroplasticity — the brain's ability to adapt, reorganize and respond to injury — and the neurotrophins that help nerve cells grow and maintain connections. Semax and selank both influence BDNF (brain-derived neurotrophic factor) in rodent research, though by different routes ^[4][11]. DSIP belongs at a more uncertain edge of the desk: it has been studied around sleep and stress signaling, but no specific receptor has been confirmed ^[14].

The pages below explain what each compound is, which models or populations researchers examined, and how much confidence the evidence supports. None is FDA-approved for human use. This is an independent literature digest, not medical advice, and it gives no human dosing guidance.

Neuroplasticity and neurotrophic signaling

Neuroplasticity is the umbrella term for how neurons form, strengthen, weaken and prune the connections between them — the physical substrate of learning, memory, mood regulation and recovery from injury. Several molecular signals drive that process, and two show up repeatedly in the semax and selank literature: BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), a related family member.

Semax's core mechanism is a rapid, region-specific rise in BDNF and NGF gene expression and protein levels after dosing in rodent studies, alongside a distinct action inhibiting enzymes that break down endogenous opioid peptides ^[4][3]. Selank's profile runs largely through a different channel — positive allosteric modulation of GABA receptors, the brain's primary inhibitory signaling system — with its own separate BDNF link documented in rat hippocampus ^[8][11]. DSIP sits apart from both: it has no identified receptor after more than forty years of study, and its evidence base is the thinnest and most inconsistently replicated of the three ^[14].

Reading them side by side is the point of this desk. Semax and selank both touch neurotrophic signaling but through different upstream routes and for different behavioral endpoints — cognitive performance and neuroprotection for one, anxiolysis for the other. DSIP's connection to the same broad neuroplasticity story is looser and its literature is explicitly described, in the review this desk relies on most, as containing "a still unresolved riddle" ^[14]. The comparison page lays out exactly where each compound's evidence is strong, and where it is thin.

What are research peptides?

A peptide is a short chain of amino acids — smaller than a full protein, but built from the same building blocks. The three compounds on this desk are all short, synthetic or naturally occurring peptides: semax is a seven-amino-acid analog of a fragment of adrenocorticotropic hormone (ACTH); selank is a seven-amino-acid analog of the endogenous immune peptide tuftsin; DSIP is a naturally occurring nine-amino-acid peptide first isolated from the cerebral venous blood of sleeping rabbits.

None of the three is an FDA-approved medicine in the United States. Semax and selank are registered pharmaceuticals in Russia for specific clinical indications, but outside that regulatory context all three are sold, where they are sold at all, as unscheduled research chemicals — material intended for laboratory research, not human consumption, with no regulator verifying its identity, purity or sterility. The great majority of the human and animal evidence for semax and selank comes from Russian and Ukrainian research groups; DSIP's older human trials are small, mostly from the 1980s, and have not been meaningfully replicated in modern controlled trials. This site reports what was studied, in whom, and how — it does not recommend using any of these compounds, and it names no human dose except as it appears inside a cited study.

Reading this desk

Each of the three peptides has its own page — semax, selank, DSIP — following the same structure: what the compound is, how it is proposed to work, what the primary research actually found, what people report using it for (clearly labeled as anecdotal, never clinical evidence), and the safety cautions worth weighing. The comparison page puts all three side by side on mechanism, evidence maturity and what each is actually studied for. The FAQ answers the specific questions readers bring most often, and every citation across the site is gathered on one shared references page.